As previously disclosed in the Current Report on Form 8-K filed by ABIOMED, Inc., with the U.S. Securities and Exchange Commission (the SEC) on November 1, 2022, the Company is party to an Agreement and Plan of Merger, dated as of October 31, 2022 (the Merger Agreement), with Johnson & Johnson and Athos Merger Sub, Inc. In accordance with the terms of the Merger Agreement, on December 21, 2022, the Company and Todd A. Trapp, the Company's Chief Financial Officer, enter into termination agreement.
Abiomed, Inc.
Equities
ABMD
US0036541003
Advanced Medical Equipment & Technology
1st Jan change | Capi. | |
---|---|---|
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B | |
+26.76% | 32.03B |